Abstract: Vascular endothelial growth factor（VEGF）is high expression in the organization of renal cell carcinoma and mainly regulate by VHL gene and hypoxic of organization. Moreover, it can be a biomarker to judge renal cell carcinoma tumor progression and prognostic. In recent years, anti-VEGF targeted drugs are used for the treatment of renal cell carcinoma and receive meaningful clinical benefits.